Difference between revisions of "How I Treat"
Jump to navigation
Jump to search
| Line 38: | Line 38: | ||
==Lymphoid neoplasms== | ==Lymphoid neoplasms== | ||
| − | ===[[Classical Hodgkin lymphoma]]=== | + | ===[[Chronic lymphocytic leukemia|Chronic lymphocytic leukemia (CLL/SLL)]]== |
| + | *'''2021:''' Lew et al. [https://ashpublications.org/blood/article-abstract/138/5/361/475780/How-I-treat-chronic-lymphocytic-leukemia-after How I treat chronic lymphocytic leukemia after venetoclax] | ||
| + | *'''2019:''' Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019 Mar 21;133(12):1298-1307. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6428663/ link to PMC article] | ||
| + | *'''2018:''' Brown JR. How I treat CLL patients with ibrutinib. Blood. 2018 Jan 25;131(4):379-386. [https://doi.org/10.1182/blood-2017-08-764712 link to original article] [https://pubmed.ncbi.nlm.nih.gov/29255067/ PubMed] | ||
| + | |||
| + | ===[[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]]=== | ||
*'''2021:''' Epperla & Herrera [https://doi.org/10.1182/blood.2020007900 How I incorporate novel agents into the treatment of classical Hodgkin lymphoma] | *'''2021:''' Epperla & Herrera [https://doi.org/10.1182/blood.2020007900 How I incorporate novel agents into the treatment of classical Hodgkin lymphoma] | ||
| − | ===[[Diffuse large B-cell lymphoma]]=== | + | ===[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]=== |
*'''2023:''' Lugtenburg & Mutsaers [https://doi.org/10.1182/blood.2020008239 How I treat older patients with DLBCL in the frontline setting] [https://pubmed.ncbi.nlm.nih.gov/36413153/ PubMed] | *'''2023:''' Lugtenburg & Mutsaers [https://doi.org/10.1182/blood.2020008239 How I treat older patients with DLBCL in the frontline setting] [https://pubmed.ncbi.nlm.nih.gov/36413153/ PubMed] | ||
Revision as of 01:45, 7 September 2023
The "How I Treat" series has been published by Blood for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered high-level expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles.
Articles are presented by condition, in reverse chronological order. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
Note: this page is currently under construction.
Malignant hematology
Myeloid neoplasms
Acute lymphoblastic leukemia
- 2023: Si Lim et al. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults PubMed
- 2023: Kopmar & Cassaday How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia PubMed
- 2020: Aldoss & Douer. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia PubMed
- 2020: Aldoss & Forman. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy PubMed
- 2019: Ravandi How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia PubMed
- 2015: Curran & Stock. How I treat acute lymphoblastic leukemia in older adolescents and young adults PubMed
- 2015: Frey & Luger. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia PubMed
Acute myeloid leukemia
- 2023: Biederstädt & Rezvani How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy PubMed
- 2021: Falini et al. How I diagnose and treat NPM1-mutated AML PubMed
- 2020: DeWolf & Tallman How I treat relapsed or refractory AML PubMed
- 2020: DiNardo & Wei. How I treat acute myeloid leukemia in the era of new drugs PubMed
- 2016: Ofran et al. How I treat acute myeloid leukemia presenting with preexisting comorbidities PubMed
- 2015: Röllig & Ehninger. How I treat hyperleukocytosis in acute myeloid leukemia PubMed
- 2014: Ossenkoppele & Löwenberg. How I treat the older patient with acute myeloid leukemia PubMed
- 2011: Bakst et al. How I treat extramedullary acute myeloid leukemia PubMed
Chronic myeloid leukemia
Myelodysplastic syndrome
- 2019: Santini How I treat MDS after hypomethylating agent failure
- 2013: Sekeres & Cutler How we treat higher-risk myelodysplastic syndromes PubMed
- 2013: Fenaux & Adès How we treat lower-risk myelodysplastic syndromes
Polycythemia vera
- 2014: Vannucchi How I treat polycythemia vera PubMed
Lymphoid neoplasms
=Chronic lymphocytic leukemia (CLL/SLL)
- 2021: Lew et al. How I treat chronic lymphocytic leukemia after venetoclax
- 2019: Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019 Mar 21;133(12):1298-1307. link to PMC article
- 2018: Brown JR. How I treat CLL patients with ibrutinib. Blood. 2018 Jan 25;131(4):379-386. link to original article PubMed
Classical Hodgkin lymphoma (cHL)
- 2021: Epperla & Herrera How I incorporate novel agents into the treatment of classical Hodgkin lymphoma
Diffuse large B-cell lymphoma (DLBCL)
- 2023: Lugtenburg & Mutsaers How I treat older patients with DLBCL in the frontline setting PubMed